Advertisement
Screener

ARS Pharmaceuticals, Inc. (SPRY) Debt Instrument, Face Amount

2.8 / 5 stars · 68/120 Roast Me

ARS Pharmaceuticals, Inc. Debt Instrument, Face Amount

ARS Pharmaceuticals, Inc. (SPRY) had Debt Instrument, Face Amount of $100.00 million as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Notes › Debt

us-gaap:DebtInstrumentFaceAmount · last filed 2026-08-13

  • 2026-06-30: Debt Instrument, Face Amount $100.00M.
  • 2026-03-31: Debt Instrument, Face Amount $100.00M.
  • 2025-12-31: Debt Instrument, Face Amount $100.00M.
  • 2025-09-30: Debt Instrument, Face Amount $100.00M.
Period endDebt Instrument, Face Amount
2026-06-30$100.00M
10-Q · filed 2026-08-13
2026-03-31$100.00M
10-Q · filed 2026-05-15
2025-12-31$100.00M
10-Q · filed 2026-08-13
2025-09-30$100.00M
10-Q · filed 2025-11-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85